Cargando…

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)

We designed a new treatment protocol incorporating concurrent administration of L-asparaginase (to reduce the probability of systemic progression during concurrent chemoradiotherapy (CCRT)) plus high-dose methotrexate to consolidation chemotherapy to intensify the regimen for treating localized extr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Dok Hyun, Kim, Seok Jin, Jeong, Seong Hyun, Shin, Dong-Yeop, Bae, Sung Hwa, Hong, Junshik, Park, Seong Kyu, Yhim, Ho-Young, Yang, Deok-Hwan, Lee, Hyewon, Kang, Hye Jin, Lee, Mark Hong, Eom, Hyeon-Seok, Kwak, Jae-Yong, Lee, Jae Hoon, Suh, Cheolwon, Kim, Won Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356760/ https://www.ncbi.nlm.nih.gov/pubmed/27542213 http://dx.doi.org/10.18632/oncotarget.11319

Ejemplares similares

Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
por: Oh, Sung Yong, et al.
Publicado: (2019)

Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study
por: Lee, Seul, et al.
Publicado: (2015)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)
por: Yoon, Dok Hyun, et al.
Publicado: (2017)

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
por: Cho, Hyungwoo, et al.
Publicado: (2023)

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study
por: Yhim, Ho-Young, et al.
Publicado: (2010)

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
por: Kim, Yu Ri, et al.
Publicado: (2023)

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Seok Jin, et al.
Publicado: (2011)

The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
por: Suh, Cheolwon, et al.
Publicado: (2017)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea
por: Kim, Seok Jin
Publicado: (2015)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

Feasibility of low-dose radiotherapy for patients with stage I/II extranodal NK-/T-cell lymphoma, nasal type achieving complete response after l-asparaginase-containing chemotherapy
por: Kim, Jae Sik, et al.
Publicado: (2022)

Organ-specific considerations for marginal zone lymphomas in Korea, based on Consortium for Improving Survival of Lymphoma (CISL) and Korean clinical studies
por: Oh, Sung Yong, et al.
Publicado: (2019)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
por: Huh, Seok Jae, et al.
Publicado: (2020)

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kim, Hyun Jee, et al.
Publicado: (2018)

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
por: Yhim, Ho-Young, et al.
Publicado: (2020)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
por: Roh, Jin, et al.
Publicado: (2020)

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Kyoung Ha, et al.
Publicado: (2023)

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
por: Zhang, Yao, et al.
Publicado: (2021)

Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement
por: Song, Moo-Kon, et al.
Publicado: (2011)

Effects of a BMI1008 mixture on postoperative pain in a rat model of incisional pain
por: Choi, Geun Joo, et al.
Publicado: (2021)

Extranodal NK/T cell lymphoma
por: Jeong, Seong Hyun
Publicado: (2020)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
por: Lin, Ningjing, et al.
Publicado: (2013)

Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea
por: Lee, Ho Sup, et al.
Publicado: (2014)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017)

The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
por: Kim, Seok Jin, et al.
Publicado: (2023)

A phase II prospective study of the “Sandwich” protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma
por: Jiang, Ming, et al.
Publicado: (2017)

Size and extranodal extension of metastatic lymph nodes in lung adenocarcinoma
por: Moon, Duk Hwan, et al.
Publicado: (2020)

Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)
por: Hong, Junshik, et al.
Publicado: (2018)

Hearing Restoration in Neurofibromatosis Type II Patients
por: Lee, Jeon Mi, et al.
Publicado: (2016)

Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial
por: Seo, Jeongkuk, et al.
Publicado: (2017)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Incidence of venous thromboembolism in Korea from 2009 to 2013
por: Hong, Junshik, et al.
Publicado: (2018)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m79o2ma3p9o767t3dq8tb38m6i